| Market Cap | 1.6B 1.4B 1.29B 1.19B 2.25B 154B 2.29B 15.41B 6.05B 75.26B 6.01B 5.88B 259B | P/E 2026 * |
173x | P/E 2027 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise Value | 1.6B 1.4B 1.29B 1.19B 2.25B 154B 2.29B 15.41B 6.05B 75.26B 6.01B 5.88B 259B | EV / Sales 2026 * |
4.59x | EV / Sales 2027 * | 3.1x |
| Free-Float |
84.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Imprimis Pharmaceuticals Inc
| 1 day | +0.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 53 | 2011-12-16 |
Andrew Boll
PSD | President | 43 | 2025-08-20 |
Brett Burrell
CMP | Compliance Officer | - | 2023-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Baum
CHM | Chairman | 53 | 2021-08-18 |
Perry Sternberg
BRD | Director/Board Member | 57 | 2022-03-30 |
Adrienne Graves
BRD | Director/Board Member | 71 | 2024-01-25 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.83% | +11.11% | - | - | 1.6B | |
| +0.35% | -4.87% | +49.87% | +157.34% | 1,031B | |
| -2.69% | -6.22% | +59.19% | +54.51% | 595B | |
| +0.44% | -3.41% | +30.97% | +79.48% | 431B | |
| +0.98% | -1.40% | +29.49% | +21.76% | 326B | |
| -0.34% | -3.10% | +27.00% | +43.60% | 277B | |
| +1.63% | -11.76% | +19.72% | +21.72% | 263B | |
| +3.39% | +2.29% | -23.68% | -37.83% | 224B | |
| +0.86% | -2.63% | +22.50% | +57.55% | 193B | |
| +1.28% | -3.03% | +20.76% | +70.62% | 164B | |
| Average | +0.67% | -3.79% | +26.20% | +52.08% | 389.37B | |
| Weighted average by Cap. | +0.21% | -4.31% | +35.59% | +76.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 348M 305M 281M 258M 489M 33.53B 498M 3.36B 1.32B 16.39B 1.31B 1.28B 56.48B | 516M 451M 416M 382M 724M 49.62B 737M 4.97B 1.95B 24.25B 1.94B 1.89B 83.59B |
| Net income | 9.81M 8.58M 7.91M 7.27M 13.78M 944M 14.02M 94.46M 37.06M 461M 36.84M 36.03M 1.59B | 92.93M 81.25M 74.95M 68.9M 131M 8.94B 133M 895M 351M 4.37B 349M 341M 15.06B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
